申请人:Boehringer Ingelheim International GmbH
公开号:US09308194B2
公开(公告)日:2016-04-12
A compound of formula I,
wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
公式I的化合物,其中R1、R2、R3、X、m和n组分的定义如权利要求1中所述,具有有价值的药理特性,特别是结合到GPR40受体并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病,例如代谢性疾病,特别是2型糖尿病。此外,本发明涉及新的中间体,用于合成公式I的化合物。